GlassScriptPhysician profile
David A Rossello
NPI 1558329771
$3,925.81
in general payments reported to CMS, 2019-2025
13 companies · $504 in 2025
The $504 reported for 2025 was more than what 77% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $327 · 2021: $435 · 2022: $502 · 2023: $701 · 2024: $1,122 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,325.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,501.57 | 2022-2025 | Infuse, Biotrue One Day, Infuse Multifocal |
| Alcon Vision LLC | $902.32 | 2020-2025 | Total30, Dailies Total1, Precision 1 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $563.61 | 2019-2021 | |
| Coopervision INC. | $405.60 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Johnson & Johnson Vision Care, INC. | $177.48 | 2020-2023 | Acuvue |
| Sun Pharmaceutical Industries INC. | $147.88 | 2020-2022 | |
| Abbvie INC. | $98.99 | 2022 | |
| Glaukos Corporation | $38.67 | 2024 | Ce-Marked Kxla System |
| Kala Pharmaceuticals, INC. | $23.19 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $17.26 | 2024 | Xdemvy |
| Thea Pharma INC. | $16.50 | 2023 | |
| Optos, INC. | $13.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rossello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.